ArticleOncogenesis2019
Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1
Article in Oncogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 67 citations in OpenAlex.
- Caveolin-1 drives immunosuppression in esophageal squamous cell carcinoma by enhancing exosome secretion and macrophage M2 polarization via inhibition of MVB autophagic degradation.Journal of translational medicine · 2026Article
- Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4/NF-κB/IL-6/STAT3 Signalling Cascade.Journal of cellular and molecular medicine · 2026Article
- Extracellular vesicles in cancer´s communication: messages we can read and how to answer.Molecular cancer · 2025Review
- TAMs and PD-1 networking in esophageal cancer: literature review.ESMO gastrointestinal oncology · 2025Review
- Exosome-Derived Cargos in Immune Microenvironment in Esophageal Carcinoma: A Mini-Review.Recent patents on anti-cancer drug discovery · 2025Review
- Exosomes in esophageal cancer: function and therapeutic prospects.Medical oncology (Northwood, London, England) · 2024Review
- Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response.Scientific reports · 2024Article
- The roles of exosomes in esophageal cancer.Discover oncology · 2024Review
- Review
- Current status of research on the mechanisms of tumor-associated macrophages in esophageal cancer progression.Frontiers in oncology · 2024Review
- HMGB1 Carried by Small Extracellular Vesicles Potentially Plays a Role in Promoting Acquired Middle Ear Cholesteatoma.Diagnostics (Basel, Switzerland) · 2023Article
- Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies.Journal of cancer research and clinical oncology · 2023Review
- Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis.Journal of translational medicine · 2023Review
- Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells.Biomolecules · 2022Review
- Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma.Angiogenesis · 2022Article
- Role of high-mobility group box 1 in cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.Frontiers in immunology · 2022Review
- Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.Frontiers in pharmacology · 2022Review
- Exploring extracellular vesicles as mediators of clinical disease and vehicles for viral therapeutics: Insights from the COVID-19 pandemic.Extracellular vesicles and circulating nucleic acids · 2022Article
- Dual role of ARPC1B in regulating the network between tumor-associated macrophages and tumor cells in glioblastoma.Oncoimmunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages constitute one of the most common components of immune cells, which penetrate tumors and they have a key role in tumor prognosis. Here, we identified an unrecognized macrophage subpopulation, which favors tumorigenesis. These macrophages express programmed cell death protein 1 (PD1) in a constitutive manner and accumulates in esophageal squamous cell carcinoma (ESCC) in advanced stage of the disease and is negatively associated with the survival of ESCC patients. The PD1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.